Trial record 4 of 97 for:
Open Studies | "Hypotension"
Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension
This study is currently recruiting participants.
Verified March 2013 by Shire Development LLC
Sponsor:
Shire Development LLC
Information provided by (Responsible Party):
Shire Development LLC
ClinicalTrials.gov Identifier:
NCT01518946
First received: January 18, 2012
Last updated: March 27, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether midodrine works against the symptoms of orthostatic hypotension caused by being on a tilt table.
| Condition | Intervention | Phase |
|---|---|---|
|
Orthostatic Hypotension |
Drug: Midodrine HCl Drug: Placebo |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Phase 4, Randomized, Double-blind, Placebo-controlled, Crossover Study to Investigate the Clinical Benefit of Midodrine Hydrochloride in Male and Female Subjects With Symptomatic Orthostatic Hypotension |
Resource links provided by NLM:
Further study details as provided by Shire Development LLC:
Primary Outcome Measures:
- Time to onset of syncope/near syncope while on tilt table [ Time Frame: 1 hour post-dose ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 18 |
| Study Start Date: | May 2012 |
| Estimated Study Completion Date: | May 2014 |
| Estimated Primary Completion Date: | May 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Midodrine HCl |
Drug: Midodrine HCl
dose at the subject's current dose level
Other Name: ProAmatine®
|
| Placebo Comparator: Placebo |
Drug: Placebo
single dose of matching placebo
|
Detailed Description:
The efficacy of midodrine will be assessed in those subjects who have severe symptoms of orthostatic hypotension when not taking midodrine and are controlled when taking midodrine. The study will involve approximately 4 overnight stays.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male and female subjects must be 18 years of age or older and ambulatory.
- Females of child-bearing potential (FOCP) must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test.
- A documented history of severe Symptomatic Orthostatic Hypotension (SOH) that, in the judgment of the treating physician, has required treatment with midodrine HCl , and has been at a stable dose for at least 3 months.
- The subject has manifested at least 1 of the following symptoms while standing or had a medical history of 1 of the following when not treated for orthostatic hypotension (OH): dizziness, lightheadedness, feeling faint, or feeling like they might black out.
Exclusion Criteria:
- The subject is a pregnant or lactating female.
- The subject has pre-existing sustained supine hypertension greater than 180mmHg systolic and 110mmHg diastolic BP or had these measurements at the Screening Visit. Sustained is defined as persistently greater at 2 separate measurements at least 5 minutes apart with the subject supine and at rest for the 5 minutes.
- Subjects taking concomitant medications of interest are excluded unless those medications are reviewed and discussed with the Medical Monitor or Study Physician and documented prior to enrolling the subject. If agreement is reached between the Investigator and Sponsor for the subject to continue in the study, all allowed medications should be maintained at a constant dose throughout the study.
- The Principal Investigator deems any clinical laboratory test (at the Screening Visit) abnormality to be clinically significant
- The subject has participated in other studies of investigational drugs or devices within 30 days prior to enrollment in this study (other than Study SPD426-406).
- Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational product or study procedures.
- The subject has a concurrent chronic or acute illness, disability, or other condition (including significant unexpected laboratory or electrocardiogram [ECG] findings) that might confound the results of the tests and/or measurements administered in this study, or that might have increased the risk to the subject.
- Known or suspected intolerance or hypersensitivity to the investigational product(s), closely-related compounds, or any of the stated ingredients.
- Prior enrollment failure or randomization in this study.
- History of alcohol abuse or other substance abuse within the last year.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01518946
Contacts
| Contact: Shire Call Center | +1 866-842-5335 |
Locations
| United States, Florida | |
| Parkinson's Disease and Movement Disorders Center of Boca Raton | Not yet recruiting |
| Boca Raton, Florida, United States, 33486 | |
| Contact: Ann Diaz 561-392-1818 | |
| Contact: Jenifer Bar-Nur 561-392-1818 | |
| Principal Investigator: Stuart Isaacson | |
| Advance Research Institute Inc | Not yet recruiting |
| New Port Richey, Florida, United States, 34653 | |
| Contact: Audrey Scalin 727-835-3261 | |
| Principal Investigator: Daniel Rodriguez, MD | |
| United States, Kansas | |
| Analab Clinical Research Inc | Recruiting |
| Lenexa, Kansas, United States, 66219 | |
| Contact: Shultz 913-221-0421 ext 350 rshultz@analabcr.com | |
| Principal Investigator: Stephen Maddock, MD, PhD | |
| United States, Minnesota | |
| Mayo Clinic | Not yet recruiting |
| Rochester, Minnesota, United States, 55905 | |
| Contact: James Schmelzer 507-284-0002 | |
| Principal Investigator: Phillip Low | |
| United States, New York | |
| Buffalo Clinical Research Center (BCRC) | Not yet recruiting |
| Buffalo, New York, United States, 14202 | |
| Contact: Robert Blum 716-885-3580 | |
| Principal Investigator: Christen Lates | |
| Columbia University | Not yet recruiting |
| New York, New York, United States, 10032 | |
| Contact: Stacy Mano 212-305-6035 | |
| Principal Investigator: Louis Weimer | |
| NYU Medical Centre | Not yet recruiting |
| New York, New York, United States, 10016 | |
| Contact: Jose Martinez 212-263-7225 | |
| Principal Investigator: Horatio Kaurmann | |
| United States, Ohio | |
| Cleveland Clinic | Not yet recruiting |
| Cleveland, Ohio, United States, 44195 | |
| Contact: Raquel Rozick 216-444-4959 | |
| Principal Investigator: Fetnat Fouad-Tarazi | |
| United States, Oregon | |
| Kidney and Hypertension Center | Not yet recruiting |
| Roseburg, Oregon, United States, 97471 | |
| Contact: Lori Romero 541-957-1133 | |
| Principal Investigator: Neil Kumar | |
| United States, Tennessee | |
| New Orleans Center for Clinical Research - Knoxville | Recruiting |
| Knoxville, Tennessee, United States, 37920 | |
| Principal Investigator: William B Smith, M.D | |
| United States, Texas | |
| The Heartbeat Clinic, PA | Recruiting |
| McKinney, Texas, United States, 75069 | |
| Contact: Alice Young 214-843-2298 ayoung@ntmtrials.net | |
| Principal Investigator: Amer Suleman | |
| United States, Utah | |
| Aspen Clinical Research | Recruiting |
| Orem, Utah, United States, 84058 | |
| Contact: Ian Dawe 801-342-5409 iand@aspenclinicalresearch.com | |
| Principal Investigator: Aaron Weaver, M.D | |
| United States, Wisconsin | |
| Aurora Cardiovascular Services | Not yet recruiting |
| Milwaukee, Wisconsin, United States, 53215 | |
| Contact: Anthony Chambers 414-385-2565 | |
| Principal Investigator: Ryan Cooley | |
Sponsors and Collaborators
Shire Development LLC
More Information
No publications provided
| Responsible Party: | Shire Development LLC |
| ClinicalTrials.gov Identifier: | NCT01518946 History of Changes |
| Other Study ID Numbers: | SPD426-406 |
| Study First Received: | January 18, 2012 |
| Last Updated: | March 27, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Shire Development LLC:
|
Symptomatic Orthostatic Hypotension |
Additional relevant MeSH terms:
|
Hypotension Hypotension, Orthostatic Vascular Diseases Cardiovascular Diseases Orthostatic Intolerance Primary Dysautonomias Autonomic Nervous System Diseases Nervous System Diseases Midodrine Sympathomimetics Autonomic Agents Peripheral Nervous System Agents |
Physiological Effects of Drugs Pharmacologic Actions Vasoconstrictor Agents Cardiovascular Agents Therapeutic Uses Adrenergic alpha-1 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 23, 2013